Observational studyNutrients2026
Vitamin D Status and Response to Calcifediol Supplementation in Term and Preterm Infants with Cholestasis.
Observational study in Nutrients, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND/
objectivesInfants with cholestasis are at risk of vitamin D status impairment; the role of prematurity remains unclear. The primary aim of this study was to characterize vitamin D status in term and preterm infants with cholestasis and to determine whether serum 25OHD concentrations were associated with gestational age, etiology of cholestasis, and biochemical markers of cholestatic activity. The secondary aim was to assess changes in serum 25OHD concentrations during calcifediol supplementation and to identify factors associated with follow-up 25OHD concentrations.
methodsIn this prospective observational study with a concurrent control group, infants with cholestasis and controls underwent assessment, including serum 25-hydroxyvitamin D (25OHD), at baseline and after calcifediol supplementation in cholestatic infants. Predictors of 25OHD were evaluated using multivariable models.
resultsWe included 127 infants: 70 with cholestasis (39 term, 31 preterm) and 57 controls (30 term, 27 preterm). Biliary atresia was diagnosed in 21 (30%) infants. Calcifediol was administered to 38 (54%) cholestatic infants: 18 (46%) term and 20 (64%) preterm at baseline. The remaining 32 infants with cholestasis were receiving vitamin D3 supplementation. Following enrollment and review of the baseline 25OHD results, calcifediol treatment was continued or initiated in 66 of the 70 infants. Treatment was discontinued in four infants based on their high serum 25OHD concentrations. Baseline 25OHD was similar in cholestasis and controls (34.81 ± 21.33 vs. 31.55 ± 10.14 ng/mL;
conclusionsVitamin D status in cholestatic infants is highly variable. Cumulative exposure of calcifediol is associated with higher 25OHD concentrations, but heterogeneous responses require monitoring and individualized dose adjustment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.